Akoya Biosciences Inc

NASDAQ:AKYA   12:44:00 PM EDT
13.09
-0.25 (-1.87%)
Products

Akoya Biosciences To Partner With Acrivon Therapeutics For The Clinical Development Of Acrivon’s Proprietary Oncosignature Test Into A Companion Diagnostic

Published: 06/28/2022 12:14 GMT
Akoya Biosciences Inc (AKYA) - Akoya Biosciences to Partner With Acrivon Therapeutics for the Clinical Development of Acrivon’s Proprietary Oncosignature® Test Into a Companion Diagnostic.
Akoya Biosciences Inc - Oncosignature Test Will Run on Co's Phenoimager Solution.
Akoya Biosciences Inc - in Partnership With Acrivon, Co Will Develop, Clinically Validate, and Seek Regulatory Co-approval for Oncosignature Test.
Akoya - in Partnership With Acrivon, Co Will Commercialize Test As Exclusive Provider of Companion Diagnostic Required for Prescribing Acr-368.